Robbie Marcus
Stock Analyst at JP Morgan
(3.88)
# 618
Out of 4,955 analysts
163
Total ratings
54.55%
Success rate
8.29%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSP Inspire Medical Systems | Downgrades: Neutral | $195 → $110 | $93.05 | +18.22% | 6 | Aug 5, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $80 → $85 | $81.39 | +4.44% | 5 | Jul 25, 2025 | |
| COO The Cooper Companies | Downgrades: Neutral | $110 → $76 | $73.50 | +3.40% | 5 | May 30, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $8.66 | +84.76% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $7.20 | -2.78% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $105.71 | -0.67% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $14.26 | -15.85% | 6 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $53.69 | +8.04% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $8.45 | +101.18% | 5 | Apr 4, 2025 | |
| MMSI Merit Medical Systems | Initiates: Overweight | $120 | $87.36 | +37.36% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $24.27 | +48.33% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $391.87 | +13.56% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $480.45 | +40.49% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $7.21 | +80.31% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $106.05 | +3.72% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $333.00 | -0.90% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $11.58 | +176.34% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $36.07 | +10.90% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $81.67 | +4.08% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $73.87 | +21.84% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $30.00 | +66.67% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $7.16 | +11.73% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $255.72 | -2.24% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $18.96 | -15.61% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $7.37 | -5.02% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $14.54 | +16.92% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $132.44 | -10.90% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $163.20 | -4.41% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $93.22 | +12.64% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $90.94 | -56.01% | 2 | May 5, 2020 |
Inspire Medical Systems
Aug 5, 2025
Downgrades: Neutral
Price Target: $195 → $110
Current: $93.05
Upside: +18.22%
Edwards Lifesciences
Jul 25, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $81.39
Upside: +4.44%
The Cooper Companies
May 30, 2025
Downgrades: Neutral
Price Target: $110 → $76
Current: $73.50
Upside: +3.40%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $8.66
Upside: +84.76%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $7.20
Upside: -2.78%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $105.71
Upside: -0.67%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $14.26
Upside: -15.85%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $53.69
Upside: +8.04%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $8.45
Upside: +101.18%
Merit Medical Systems
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $87.36
Upside: +37.36%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $24.27
Upside: +48.33%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $391.87
Upside: +13.56%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $480.45
Upside: +40.49%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $7.21
Upside: +80.31%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $106.05
Upside: +3.72%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $333.00
Upside: -0.90%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $11.58
Upside: +176.34%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $36.07
Upside: +10.90%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $81.67
Upside: +4.08%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $73.87
Upside: +21.84%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $30.00
Upside: +66.67%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $7.16
Upside: +11.73%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $255.72
Upside: -2.24%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $18.96
Upside: -15.61%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $7.37
Upside: -5.02%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $14.54
Upside: +16.92%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $132.44
Upside: -10.90%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $163.20
Upside: -4.41%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $93.22
Upside: +12.64%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $90.94
Upside: -56.01%